Page Image

HR Breast Cancer

Back to Homepage
EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer
Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data.
Advertisement

Expert Interviews

Advertisement
Advertisement
Latest Updates in Breast Cancer

May 22, 2025